BGBIO
BERGENBIO
Siste
1,26 NOK
+0,008 (↑ 0,64%)
- Tid
- 25. jul.
- Markedsverdi
- 49,17 mill.
- Kjøp
- 1,20
- Selg
- 1,38
- Høy
- 1,29
- Lav
- 1,20
- Volum
- 169 923,00
- Omsetning
- 209 916,05
Dag
↑ 0,64%
Uke
↑ 16,05%
Mnd
↓ 10,14%
YTD
↓ 84,62%
År
↓ 90,21%
3 år
↓ 99,90%
5 år
↓ 99,97%
10 år
-
Ordredybde
| Volum | Kjøp | Selg | Volum | |
|---|---|---|---|---|
| 1 000 | 1,20 | 1,38 | 5 000 | |
| 5 000 | 1,00 | 1,47 | 1 200 | |
| 1 400 | 0,97 | 1,50 | 1 800 | |
| 900 | 0,92 | 1,55 | 410 | |
| 900 | 0,82 | 1,84 | 8 589 |
MeglerhusanbefalingerOppdatert 25. jul.
Børsmeldinger
30. jun 2025kl. 20:30
BerGenBio ASA - Key information related to the rights issue →30. jun 2025kl. 20:05
Announcement of fully underwritten rights issue →30. jun 2025kl. 20:00
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue →26. jun 2025kl. 09:29
BerGenBio ASA - Minutes from the annual general meeting 2025 →03. jun 2025kl. 17:22
BerGenBio ASA: Update on Strategic Review Process and Status of Activities →03. jun 2025kl. 13:55
BerGenBio ASA: Notice of Annual General Meeting →30. apr 2025kl. 07:51
Financial calendar →29. apr 2025kl. 20:03
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar →26. mar 2025kl. 06:00
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients →17. mar 2025kl. 06:00
BerGenBio announces advancement of its strategic review →Finanskalender
19. aug 2025Halvårsrapport
Største eiere
EierAndel
METEVA AS
23,05%
NORDNET LIVSFORSIKRING AS
2,46%
BERA AS
2,14%
MARSTIA INVEST AS
2,01%
HOLMEFJORD IVAR
1,92%
DANSKE BANK A/S
1,67%
NORDNET BANK AB
1,63%
JAKOB HATTELAND HOLDING AS
1,35%
HAWKEYE INVEST AS
1,34%
AUTO SPAR AS
1,30%
Andre
61,12%